Hepatitis C at epidemic levels among young injectors in London

November 11, 2004

Levels of hepatitis C among young injecting drug users across London are reaching epidemic levels report researchers from Imperial College London, the Health Protection Agency and the London School of Hygiene and Tropical Medicine.

According to research published today in the British Medical Journal, four in ten new young injectors now has hepatitis C, while three per cent are now infected with HIV.

Hepatitis C, which can cause serious and sometimes fatal liver damage, is mainly spread by sharing needles and syringes. Preventing HCV transmission among injecting drug users is critical to avoiding significant later health consequences in the population and associated treatment costs.

Dr Ali Judd, from Imperial College London, based at Charing Cross Hospital, and one of the authors of the study, comments: "Hepatitis C is now spreading at epidemic levels across London and HIV incidence is worryingly high, which if unchecked will lead to an increase in the total number of HIV infections. There is an urgent need for new and comprehensive programmes to tackle this growing problem."

For the study, the researchers recruited 428 injecting drug users, aged below 30 years or who had been injecting for six years or less, and followed them up one year later. The study was made possible through the use of saliva and blood spot tests for HCV and HIV developed at the Health Protection Agency Centre for Infections. Of those that were HCV negative or HIV negative at the first interview they found 42 percent and 3.4 percent were infected with HCV and HIV respectively one year later. The researchers also found high levels of syringe sharing, with one in four reporting injecting with needles and syringes that had been used by someone else in the last four weeks and one in two sharing other injecting paraphernalia.

Dr Matthew Hickman from Imperial College London, based at Charing Cross Hospital, and one of the authors of the study, comments: "For the past 6 or 7 years, government drug policy has focused on drugs and crime, and has been successful in expanding specialist drug treatment, especially through referral from criminal justice. However, there is a need now to re-invigorate harm reduction policies that prevent transmission of HCV and HIV."

The researchers believe a number of factors may have contributed to the rise in the incidence of HCV and HIV. These include a rise in the number of injectors, without any increase in the number of syringes distributed through syringe programmes, more risky injecting behaviour in newer injecting drug users, and greater levels of crack injection. There has also been a lack of targeted health promotion campaigns about hepatitis C in recent years.
-end-
The study was funded by the Policy Research Programme of the Department of Health.

Imperial College London

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.